Wrap Ups

New targets and innovative therapies for multiple myeloma were highlighted in two sessions presented at ONS 2023. Read More ›

Specific factors to be considered are outlined for the management of multiple myeloma treated with certain therapies. Read More ›

Common treatment-related adverse events and management approaches to multiple myeloma were outlined in three separate sessions at the ONS 2023 Congress. Read More ›

Approaches to help build healthcare professional and patient relationships and considerations for symptom management by patients with multiple myeloma are discussed. Read More ›

Healthcare disparities among Black and LGBTQ+ and gender minorities negatively impact clinical outcomes and survivorship. Read More ›

Capivasertib plus fulvestrant’s PFS advantage benefitted a broader patient population, and overall survival (OS) data with improved biomarker analyses can now be reported. Read More ›

DESTINY-Breast04 is the first trial comparing outcomes with trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients with HER2-low metastatic breast cancer treated with 1 or 2 prior lines of chemotherapy. Read More ›

Pembrolizumab plus chemotherapy increased event-free survival compared with chemotherapy alone, highlighting the relevance of neoadjuvant pembrolizumab therapy for improving survival in patients with early triple-negative breast cancer. Read More ›

Patients with hormone receptor (HR)-positive/HER2-negative metastatic breast cancer who had previously advanced on any cyclin-dependent kinase (CDK)4/6 inhibitor plus any endocrine therapy (ET) showed a substantial progression-free survival (PFS) advantage in the ribociclib-treated cohort. Read More ›

The TROPiCS-02 study aims to confirm optimal treatment choice in patients with hormone receptor–positive/HER2-negative metastatic breast cancer whose disease progresses after having received endocrine therapy (ET) plus cyclin-dependent kinase (CDK)4/6 inhibitor. Read More ›

Page 1 of 3